High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

Leukemia

Volumn 24, Issue 6, 2010, Pages 1139-1145

  Boultwood, J ^a   Perry, J ^a   Zaman, R ^a   Fernandez Santamaria, C ^a   Littlewood, T ^a   Kusec, R ^b   Pellagatti, A ^a   Wang, L ^c   Clark, R E ^c   Wainscoat, J S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Zagreb   (Croatia)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

ASXL1 gene; CML; SNP array analysis; UPD

Indexed keywords

PROTEIN P53; ASXL1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; ASXL1 GENE; BLAST CELL CRISIS; CHROMOSOME 8; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; GENE; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; DNA MICROARRAY; GENE DOSAGE; GENETICS; HUMAN GENOME; KARYOTYPING; MUTATION; PATHOLOGY;

BLAST CRISIS; DISEASE PROGRESSION; GENE DOSAGE; GENOME, HUMAN; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UNIPARENTAL DISOMY;

EID: 77954583280     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.65     Document Type: Article

References (42)

1. Hughes T, Goldman JM. Hematology, Basic Principles and Practice, 2nd edn. Churchill Livingstone: New York, 1995; 854-869.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002; 16: 1402-1411.
4. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432. (Pubitemid 37211057)
5. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042. (Pubitemid 32267973)
7. Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett 2009; 274: 1-9.
8. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76-94. (Pubitemid 34264171)
9. Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000; 96: 358-361. (Pubitemid 30456494)
10. Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006; 20: 671-679.
11. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 6783-6787. (Pubitemid 19236343)
12. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022. (Pubitemid 38685338)
13. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114. (Pubitemid 351630327)
14. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771-777. (Pubitemid 35007381)
15. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37. (Pubitemid 43990609)
16. Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 2008; 93: 994-1000. (Pubitemid 351957016)
17. Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica 2004; 89: 865-866. (Pubitemid 38981349)
18. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
19. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
20. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373. (Pubitemid 350106331)
21. Gibson J, Morton NE, Collins A. Extended tracts of homozygosity in outbred human populations. Hum Mol Genet 2006; 15: 789-795. (Pubitemid 43264703)
22. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629. (Pubitemid 46744292)
23. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005; 65: 9152-9154. (Pubitemid 41507976)
24. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65: 375-378.
25. Tagawa H, Karnan S, Kasugai Y, Tuzuki S, Suzuki R, Hosokawa Y et al. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8. Oncogene 2004; 23: 2576-2581. (Pubitemid 38520755)
26. Sakabe T, Shinomiya T, Mori T, Ariyama Y, Fukuda Y, Fujiwara T et al. Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization. Cancer Res 1999; 59: 511-515. (Pubitemid 29076040)
27. Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X et al. Sox7 is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 2008; 6: 1421-1430.
28. Zhang Y, Huang S, Dong W, Li L, Feng Y, Pan L et al. SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer Lett 2009; 277: 29-37.
29. Gribble SM, Reid AG, Roberts I, Grace C, Green AR, Nacheva EP. Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation. Genes Chromosomes Cancer 2003; 37: 346-358. (Pubitemid 36775777)
30. Hosoya N, Sanada M, Nannya Y, Nakazaki K, Wang L, Hangaishi A et al. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer 2006; 45: 482-494.
31. Gonzalez MA, Tachibana KE, Laskey RA, Coleman N. Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 2005; 5: 135-141. (Pubitemid 40215861)
32. Geay JF, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005; 65: 2676-2683. (Pubitemid 40490067)
33. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48-58.
34. Kagara N, Tanaka N, Noguchi S, Hirano T. Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci 2007; 98: 692-697. (Pubitemid 46563445)
35. Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM et al. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 2005; 85: 600-607. (Pubitemid 40463696)
36. Bras M, Yuste VJ, Roue G, Barbier S, Sancho P, Virely C et al. Drp1 mediates caspase-independent type III cell death in normal and leukemic cells. Mol Cell Biol 2007; 27: 7073-7088. (Pubitemid 47549746)
37. Papagerakis S, Shabana AH, Depondt J, Gehanno P, Forest N. Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum Pathol 2003; 34: 565-572. (Pubitemid 36750368)
38. Mertens C, Kuhn C, Moll R, Schwetlick I, Franke WW. Desmosomal plakophilin 2 as a differentiation marker in normal and malignant tissues. Differentiation 1999; 64: 277-290. (Pubitemid 29250934)
39. Fisher CL, Randazzo F, Humphries RK, Brock HW. Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. Gene 2006; 369: 109-118. (Pubitemid 43327337)
40. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA 2008; 105: 17050-17054.
41. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998; 16: 1013-1021. (Pubitemid 28108735)
42. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 1998; 95: 12410-12415. (Pubitemid 28483779)